$FENC
FENNEC PHARMACEUTICALS INC.

2015 Form 10-K Financial Statement

#000114420416090604 Filed on March 28, 2016

View on sec.gov

Income Statement

Concept 2015 2014 Q4 2014
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.630M $630.0K $2.520M
YoY Change -35.32% 90.91% 89.47%
% of Gross Profit
Research & Development $256.0K $170.0K $357.0K
YoY Change -28.29% 88.89% -38.34%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $256.0K $790.0K $357.0K
YoY Change -28.29% 88.1% -38.34%
Operating Profit -$1.890M -$2.877M
YoY Change -34.31% 48.99%
Interest Expense $1.230M $2.180M $700.0K
YoY Change 75.71% 42.48%
% of Operating Profit
Other Income/Expense, Net $1.231M $701.0K
YoY Change 75.61% -81.44%
Pretax Income -$658.0K $1.390M -$1.327M
YoY Change -50.41% 25.23% -150.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$659.0K $1.390M -$2.176M
YoY Change -69.72% 25.23% -217.94%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.22
Diluted Earnings Per Share -$0.06 $140.4K -$0.22
COMMON SHARES
Basic Shares Outstanding 10.83M shares 9.861M shares 9.871M shares
Diluted Shares Outstanding 10.83M shares 9.871M shares

Balance Sheet

Concept 2015 2014 Q4 2014
SHORT-TERM ASSETS
Cash & Short-Term Investments $940.0K $2.310M $2.310M
YoY Change -59.31% 39.16% 39.16%
Cash & Equivalents $940.0K $2.307M $2.310M
Short-Term Investments
Other Short-Term Assets $80.00K $17.00K $70.00K
YoY Change 14.29% 112.5% -22.22%
Inventory
Prepaid Expenses $48.00K
Receivables
Other Receivables
Total Short-Term Assets $1.020M $2.370M $2.370M
YoY Change -56.96% 35.43% 35.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $2.000K $0.00
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $1.020M $2.370M $2.370M
Total Long-Term Assets $0.00 $2.000K $0.00
Total Assets $1.020M $2.372M $2.370M
YoY Change -56.96% 35.39% 35.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $308.0K $310.0K
YoY Change -3.23% 45.28% 47.62%
Accrued Expenses $90.00K $132.0K $130.0K
YoY Change -30.77% 0.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $470.0K $1.759M $1.760M
YoY Change -73.3% -45.15% -45.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $470.0K $1.759M $1.760M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $470.0K $1.759M $1.760M
YoY Change -73.3% -45.15% -45.17%
SHAREHOLDERS EQUITY
Retained Earnings -$110.9M
YoY Change 2.0%
Common Stock $110.2M
YoY Change 4.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $550.0K $613.0K $610.0K
YoY Change
Total Liabilities & Shareholders Equity $1.020M $2.372M $2.370M
YoY Change -56.96% 35.39% 35.43%

Cashflow Statement

Concept 2015 2014 Q4 2014
OPERATING ACTIVITIES
Net Income -$659.0K $1.390M -$2.176M
YoY Change -69.72% 25.23% -217.94%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.860M -$470.0K -$1.699M
YoY Change 9.48% 6.82% -23.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $2.182M
YoY Change -100.0% 38.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.0K 2.180M $2.343M
YoY Change -78.66% 38.85% 49.24%
NET CHANGE
Cash From Operating Activities -1.860M -470.0K -$1.699M
Cash From Investing Activities 0.000 0.000 $0.00
Cash From Financing Activities 500.0K 2.180M $2.343M
Net Change In Cash -1.360M 1.710M $644.0K
YoY Change -311.18% 51.33% -200.63%
FREE CASH FLOW
Cash From Operating Activities -$1.860M -$470.0K -$1.699M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
349000 USD
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
434000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
97000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
627000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1862000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1699000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1365000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
644000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1663000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
497000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2343000 USD
CY2015 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
28000 USD
CY2014 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-33000 USD
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-16000 USD
CY2014 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2000 USD
CY2015Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10940000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10940000 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
69153000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1019000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
548000 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41685000 USD
CY2015 us-gaap Revenues
Revenues
0 USD
CY2014 us-gaap Revenues
Revenues
0 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111533000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2520000 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
68656000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-1890000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2372000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-2877000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1634000 USD
CY2015 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1237000 USD
CY2014 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
355000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41588000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110874000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
613000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1231000 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
701000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-659000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-2176000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
256000 USD
CY2015 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
357000 USD
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
96000 USD
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 USD
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9871000 shares
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9871000 shares
CY2014 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
140000 USD
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10593000 shares
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000 USD
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5000 USD
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10827000 shares
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9871000 shares
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
294000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1327000 USD
CY2015 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2014 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
13000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-40000 USD
CY2015Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
942000 USD
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2307000 USD
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10827000 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10827000 shares
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
942000 USD
CY2015Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
82000 USD
CY2015Q4 us-gaap Cash
Cash
25000 CAD
CY2015Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
82000 USD
CY2014Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1319000 USD
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001211583
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q2 dei Entity Public Float
EntityPublicFloat
15222623 USD
CY2015 dei Trading Symbol
TradingSymbol
FENCF
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10939500 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10593000 shares
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-952000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-849000 USD
CY2015 fencf Gain Loss Before Income Taxes
GainLossBeforeIncomeTaxes
-658000 USD
CY2014 fencf Gain Loss Before Income Taxes
GainLossBeforeIncomeTaxes
-2176000 USD
CY2015 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-174000 USD
CY2014 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-577000 USD
CY2015 fencf Permanent Difference
PermanentDifference
-301000 USD
CY2014 fencf Permanent Difference
PermanentDifference
96000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1297000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2863000 USD
CY2015 fencf Effective Income Tax Rate Reconciliation Effect Of Noncapital Losses Expired
EffectiveIncomeTaxRateReconciliationEffectOfNoncapitalLossesExpired
1318000 USD
CY2014 fencf Effective Income Tax Rate Reconciliation Effect Of Noncapital Losses Expired
EffectiveIncomeTaxRateReconciliationEffectOfNoncapitalLossesExpired
3344000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-1455000 USD
CY2014 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-349000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2595000 shares
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000 USD
CY2014 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
21000 USD
CY2014 fencf Exchange Of Warrants
ExchangeOfWarrants
840000 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2182000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650 pure
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23010000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24307000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
23010000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
24307000 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2182000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
48000 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
449000 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
21000 USD
CY2015Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
1024000 USD
CY2015 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On August 10, 2011, and again on May 28, 2014, the Board of Directors approved a 1-for-18 and a 1-for-3 reverse stock split, or “Share Consolidation”, respectively, which became effective on August 25, 2011 and September 3, 2014, respectively. The combined 1-for-54 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date.
CY2015 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
449000 USD
CY2015Q4 us-gaap Cash
Cash
12000 USD
CY2014Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
540000 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M10D
CY2015Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber
1094000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><b>Use of estimates</b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation.&#160;Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
366000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
62000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
97000 USD
CY2015 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
-450000 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
4000 USD
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-13000 USD
CY2014 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
0 USD

Files In Submission

Name View Source Status
0001144204-16-090604-index-headers.html Edgar Link pending
0001144204-16-090604-index.html Edgar Link pending
0001144204-16-090604.txt Edgar Link pending
0001144204-16-090604-xbrl.zip Edgar Link pending
fencf-20151231.xml Edgar Link completed
fencf-20151231.xsd Edgar Link pending
fencf-20151231_cal.xml Edgar Link unprocessable
fencf-20151231_def.xml Edgar Link unprocessable
fencf-20151231_lab.xml Edgar Link unprocessable
fencf-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v433857_10k.htm Edgar Link pending
v433857_ex31-1.htm Edgar Link pending
v433857_ex31-2.htm Edgar Link pending
v433857_ex32-1.htm Edgar Link pending